Plain-English Summary
STEP 5 extends the semaglutide obesity evidence window to two years, showing sustained weight-loss benefit while treatment continues.
Key Findings
- Semaglutide produced sustained mean weight loss over 104 weeks compared with placebo.
- The trial supports the idea that continued treatment can maintain large weight loss beyond the 68-week STEP 1 time horizon.
- Improvements in waist circumference and cardiometabolic risk markers were directionally consistent with sustained weight reduction.
- Gastrointestinal adverse events remained an important tolerability signal.
Limitations
- STEP 5 was much smaller than STEP 1, so it is less definitive for less common events or subgroup claims.
- The study still does not answer what happens after discontinuation at two years.
- Trial monitoring and lifestyle support may not match routine consumer use.
Why It Matters
It helps the site avoid treating STEP 1 as a one-off short-term result and gives stronger support for claims about persistence of effect under continued treatment.
Viral Vitalism Verdict
Good longer-duration efficacy evidence, but still not a free pass on long-term strategy, adverse effects, real-world adherence, or what happens when treatment stops.
Sources
- Two-year effects of semaglutide in adults with overweight or obesity - Nature Medicine